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Policy Forum
This is the ﬁrst of three articles in the November 
2007 issue on developing new drug treatments for 
tuberculosis.
E
arly stage drug discovery is a 
key bottleneck in the pipeline 
to ﬁnd novel drugs for 
tuberculosis (TB) [1,2]. For diseases 
that affect people in wealthy countries, 
pharmaceutical companies actively 
scout advances in basic research in 
search of new and potentially lucrative 
drug targets. For TB, this is not the 
case: of the 1,556 new chemical entities 
marketed worldwide between 1975 and 
2004, only three were for TB [3]. The 
general problem of antibiotic research 
and development (R&D) has been 
described elsewhere [4,5], but TB is 
worth singling out: it is the leading 
cause of death from bacterial infection, 
it is spread person to person, and it 
is a particular threat for nosocomial 
transmission, with a potentially lethal 
impact on health care workers [6]. 
The few companies newly engaged 
in TB drug development remain risk-
averse, generally embarking on drug 
development only when given evidence 
of rigorously validated targets and 
lead compounds that inhibit them. 
The Global Alliance for TB Drug 
Development, a product development 
partnership devoted to fostering 
preclinical and clinical development 
of new TB drugs, has helped to move 
the few available lead compounds 
into development (Figure 1), but has 
had limited impact on early stages of 
TB drug discovery. Consequently, it 
has fallen in large part to academia to 
undertake early stage drug discovery. 
In practical terms, though, the lack of 
sustained funding for drug discovery 
and lack of access to industrial 
expertise and facilities, including 
medicinal chemistry, are major 
obstacles.
While the existence of a TB drug 
pipeline after decades of virtually 
no TB drug R&D is welcome, there 
are still far too few compounds that 
represent new chemical classes with 
novel mechanisms of action and 
a low probability of encountering 
pre-existing drug resistance. Of the 
approximately 40 compounds in the 
current pipeline, it is unlikely that 
a useful therapy will emerge, given 
that only about one compound in 20 
successfully emerges from an anti-
infective drug discovery program [7]. 
Since new drugs for TB should only 
be used in combination, to prevent 
resistance, it would be a responsible 
act of global leadership to take 
whatever steps are necessary to attract 
approximately 60 new lead compounds 
into the pipeline as quickly as possible. 
Nothing less will avert the escalation of 
what is already a major public health 
catastrophe.
Key Obstacles in Current Initiatives
Despite some important recent 
initiatives—most notably those 
supported by the United States 
National Institutes of Health, the 
European Union, and the Bill & 
Melinda Gates Foundation, and 
R&D units set up by Novartis, 
GlaxoSmithKline, AstraZeneca, and 
Sanoﬁ-Aventis—major limitations 
remain. It is becoming clear that 
current funding paradigms and 
strategic approaches have not led to 
the increase in drug discovery activities 
that will be required to respond to the 
emergency posed by TB. 
Overall funding for TB research 
in general, and drug discovery 
in particular, remains alarmingly 
inadequate. The ﬁght against HIV/
AIDS has been greatly fostered by the 
launch of speciﬁc research programs 
and the creation of dedicated 
research agencies at the national 
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Summary Points
u For the ﬁrst time in decades, there is 
a TB drug pipeline, but the paucity of 
candidates is still cause for alarm given 
the global emergence of drug-resistant 
TB
u Early-stage drug discovery represents 
one of the key bottlenecks in the 
search for new anti-TB drugs
u Scientists, clinicians, and 
pharmaceutical, government, and 
foundation representatives met in 
January at a symposium organized 
by Médecins Sans Frontières to 
consider urgent actions to address the 
roadblocks in TB drug R&D
u Participants discussed new approaches 
to ensure collaboration, innovation, 
and sustained application of academic 
and industry expertise to address 
major neglected diseases like TB
u Experts widely recognized the 
need to create alternative incentive 
mechanisms to stimulate R&D not 
through high pricing of medicines, 
but rather, by rewarding the impact of 
inventions on health care outcomesPLoS Medicine  |  www.plosmedicine.org 1723 November 2007  |  Volume 4  |  Issue 11  |  e293
level, such as France’s “Agence 
Nationale de Recherches sur le Sida.” 
In contrast, TB research is funded 
in competition with all other areas 
of biomedicine and is clearly not 
receiving funds commensurate with 
the global dimension of the disease 
and the probability that untreatable 
forms of TB will become increasingly 
widespread.
Another critical obstacle is the 
lack of access to information, 
pharmaceutical expertise, compounds, 
and research tools. There would be 
great value, for example, in a publicly 
accessible database that collected 
thorough information about screenings 
of compounds and about analyses that 
indicate which targets in Mycobacterium
tuberculosis appear to be “druggable.” 
Considering the limited resources for 
TB drug development, it is critical to 
avoid repetitive efforts, particularly 
multiple independent journeys to a 
dead-end.
The attempts to build fruitful 
collaborations between academia 
and industry in drug discovery are 
hampered by the failure to address 
access considerations in the licensing 
agreements that underpin such 
collaborations. Recent proposals 
suggest ways to move forward. For 
example, Equitable Access Licensing 
provides an approach to commercial 
exploitation of scientiﬁc research 
results that ensures optimal access to 
discoveries originating from academia 
when derivative technologies and/or 
products can be used in low- and 
middle-income countries [8]. While 
there are encouraging examples 
of such open licensing approaches 
related to discoveries of importance 
to the developing world, the use of 
doi:10.1371/journal.pmed.0040293.g001
Figure 1. Global TB Drug Pipeline, January 2007
(Figure: Kindly provided by STOP TB Partnership Working Group on New TB Drugs) 
BTTTRI, Beijing Tuberculosis and Thoracic Tumor Research Institute; CDC, Centers for Disease Control and Prevention; DMID, Division of Microbiology 
and Infectious Diseases; ITR, Institute for Tuberculosis Research; KRICT, Korean Research Institute of Chemical Technology; NERC, Natural Environment 
Research Council; NIAID, National Institute of Allergy and Infectious Disease; NIH, National Institutes of Health; TAACF, Tuberculosis Antimicrobial 
Acquisition and Coordinating Facility; TBRU, Tuberculosis Research Unit; TBTC, Tuberculosis Trials Consortium; TDR, Special Programme for Research 
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such licenses must become the norm. 
Indeed, the recent Philadelphia 
Consensus Statement on university 
policies for health-related innovations 
argues that universities should: 
“require the inclusion of licensing 
terms in exclusive technology transfer 
agreements that ensure low-cost access 
to health-related innovations in the 
developing world” [9].
Transfer of compounds from 
industry libraries to academia has 
also been complicated by legal and 
intellectual property issues. Some 
pharmaceutical companies have given 
universities access to small subsets of 
industry compound collections, but this 
usually requires lengthy negotiations 
to deﬁne legal agreements on a case-
by-case basis, making the whole process 
too slow to allow a productive interface 
with university investigators.
The lack of appropriate compound 
libraries for anti-infectives presents yet 
another obstacle, for academics and 
industrial scientists alike. In academia, 
combinatorial chemical libraries are 
likely to be of low yield, and those that 
are affordable may be of low quality, 
or may not include access to ready 
re-supply, which is necessary to work 
up hits that appear promising in early 
stages.
The principal strategies that are 
currently used to enhance drug 
discovery for neglected diseases such 
as TB are the creation of consortia 
that merge academic and industrial 
expertise to run “virtual” drug discovery 
projects and the establishment of drug 
discovery centers in the public sector. 
These strategies help enhance activities 
in the ﬁeld, and have brought some 
successful outcomes in ﬁnding new 
treatments for other neglected diseases 
[10,11]. Drug discovery, though, 
especially in the early stages, requires 
continuous interactive exchange 
among scientists from a broad range of 
disciplines that is not easy to reproduce 
on a virtual basis. Furthermore, to build 
drug discovery know-how in academic 
and public settings is a daunting task, 
because the recent limited increase in 
access to screening facilities has not 
been matched by the requisite access 
to medicinal chemistry and other 
pharmaceutical expertise.
Possible Ways Forward
One possible approach for generating 
a signiﬁcant scale-up of TB drug 
discovery is to improve public sector 
capacity for running drug discovery 
programs. Government funding 
agencies could establish a medicinal 
chemistry resource center that would 
work as a core facility offering free lead 
optimization and ADMET (absorption, 
distribution, metabolism, excretion, 
and toxicology) studies in animal 
models. Such a facility would be 
directed by scientists with experience 
in drug discovery, and could also 
carry out training activities in order to 
ensure medicinal chemistry expertise 
in academia. 
A major challenge, though, would be 
attracting talented scientists to the not-
for-proﬁt medicinal chemistry sector 
and retaining them in competition 
with industry. Moreover, to invest in 
medicinal chemistry for the public 
sector without the other technologies, 
resources, and expertise that go into 
drug development might result in 
limited success or strategic failure.
An alternative could be for 
governments to create incentives 
for pharmaceutical and biotech 
companies to run in-house phenotypic 
screens for anti-TB drugs with 
all available existing compound 
libraries. The scientiﬁc rationale is 
that target-based approaches have 
been unsuccessful in the area of anti-
infective agent discovery [7], whereas 
two new potential antimicrobial agents, 
platensimycin, and the diarylquinoline, 
R207910, have recently emerged 
from whole organism screens [12,13]. 
However, shortening TB chemotherapy 
requires the discovery of drugs able 
to kill dormant M. tuberculosis [14], 
justifying the search for new molecular 
targets belonging to dormancy–related 
metabolic pathways and the need 
for target-based screens. Given the 
urgency, both target-based screening 
and phenotypic screening should be 
pursued in parallel to increase the 
chances of ﬁlling the TB pipeline. 
Unfortunately, there is limited 
expertise in the private sector in 
working with M. tuberculosis and a 
shortage of the specialized facilities 
required, such as robotically equipped 
biosafety level 3 containment facilities.
The decision to invest in replicating 
drug discovery expertise and facilities 
outside industry or the identiﬁcation 
of effective incentives for companies to 
step into drug discovery for neglected 
diseases might require further strategic 
thinking, as will be discussed in the 
next paragraph. But investing in the 
creation of optimized compound 
libraries for the discovery of anti-
infectives is a realistic proposition 
that needs to be taken into serious 
consideration.
A New Paradigm for Financing 
R&D
Ultimately the gaps in TB drug 
discovery reﬂect the structural 
limitations of the current patent system 
as it is applied to generate incentives 
for essential medical R&D. To feed and 
advance the drug and vaccine pipelines 
for diseases that offer little traditional 
market incentive will require a mutually 
reinforcing alignment of three 
fundamental processes: innovation, 
incentive, and access. 
First and foremost, alternatives are 
needed to the current system, which 
encourages drug development through 
patent-based monopoly pricing. Such 
alternative incentive mechanisms 
could stimulate R&D not through 
high pricing of medicines, but rather 
by rewarding the impact of inventions 
on health care outcomes [15,16]. 
Talks held by the World Health 
Organization’s Intergovernmental 
Working Group on a global R&D 
framework treaty may hold some 
promise in suggesting alternatives to 
stimulate R&D in parallel to current 
market incentives. 
However, given the problems of 
limited expertise in industry in the 
biology of neglected diseases—and 
given the general lack of success in 
recent years for industrial efforts to 
develop anti-infectives in general 
[4]—even the addition of an effective 
incentive system to engage biotech 
and pharmaceutical companies may 
not, by itself, quickly ﬁll the pipelines 
for TB and other neglected diseases. 
Thus, the development of “open-access 
drug discovery entities” could be a 
new engine for academia–industry 
collaborations [4,16]. Open-access drug 
discovery entities would help overcome 
the obstacles that have hampered 
anti-infective development in recent 
years by offering sites for scientists to 
experiment with innovative approaches 
and generate optimized compound 
libraries for screening of anti-infectives. 
They would provide academic scientists 
with easy access to essential tools and 
expertise, possibly resulting in the PLoS Medicine  |  www.plosmedicine.org 1725 November 2007  |  Volume 4  |  Issue 11  |  e293
optimization and scaling up of drug 
discovery activities undertaken in the 
public sector. 
In addition, an open-access strategy 
would offer the great advantage 
of sharing results at the earliest 
opportunity and would work toward the 
development of speciﬁc combination 
therapies. Indeed, in the open-
access drug discovery entities model, 
government-funded contracts would 
make it feasible for participating 
companies to allow scientists from 
academia or biotech into designated 
sites where, on a fee-for-service basis, 
they could have access to the full 
suite of pharmaceutical expertise 
and technology required for team-
based drug discovery. This would 
offer a crucial solution, allowing close 
collaboration among academic and 
industry scientists and eliminating 
drawbacks of virtual drug discovery. 
Representatives of Novartis and 
GlaxoSmithKline have stated that their 
facilities in Singapore and Tres Cantos, 
Spain, respectively, are already open to 
hosting academic scientists to carry out 
focused collaborative projects, while 
AstraZeneca India is pursuing a similar 
policy. This interest from industry gives 
hope that although these companies 
do not yet function on an open-access 
basis, pilot experiments could expand 
on the base already in place in some 
pharmaceutical companies.
One of the most important functions 
of such open-access drug discovery 
entities would be to collect, generate, 
and house chemical libraries likely to 
be rich sources for anti-infective agents 
[16]. These libraries would feature 
natural products or synthetic products 
based on natural chemophores, 
collected from or inspired by a much 
wider range of organisms than those 
which typically stocked company 
collections before the advent of 
combinatorial chemistry. The anti-
infective libraries could also include 
compounds that drug companies 
have already developed for infectious 
diseases but set aside—for example, 
because they lack broad-spectrum 
activity.
These initiatives would be funded by 
users and governments and managed 
by a portfolio management committee 
including pharmaceutical professionals. 
Its task would be to evaluate submitted 
projects, select them for funding, and 
monitor their progression. 
The chief objection to open-
access drug discovery entities will 
probably be on issues of intellectual 
property. Hence we recommend that 
the governing contracts spell out a 
generic policy that does not require 
case-by-case negotiation and that 
includes mandatory procedures for 
arbitrating disputes without litigation. 
Acceptance will be fostered by 
sharing inventorship among all who 
contributed. What is critical is not the 
ownership of intellectual property but 
its control, and this should be vested 
with the funders in order to guarantee 
that people who need the resulting 
products will have access to them.
One way to ensure that priority 
medical needs are met while providing 
economic incentives is to register 
resulting patents under a patent track 
that rewards products based on the 
impact they have in reducing the global 
burden of disease [15,17]. A critical 
challenge in the implementation of 
such a model is the establishment of a 
treaty-based system to create a funding 
pool as well as the need to set clear 
criteria to judge the impact of new 
products on the burden of disease.
Although detailed modeling is still 
needed to deﬁne technical and legal 
details and economic parameters, new 
paradigms for encouraging early stage 
drug discovery will be of paramount 
importance if the TB drug pipeline is 
to address the daunting and urgent 
global needs.  
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